VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.09, Zacks reports. The company had revenue of ($0.01) million for the quarter, compared to the consensus estimate of $0.18 million. VistaGen Therapeutics had a negative return on equity of 58.88% and a negative net margin of 6,777.08%. During the same quarter last year, the business posted ($0.25) EPS.
VistaGen Therapeutics Stock Down 2.9%
Shares of NASDAQ:VTGN opened at $2.00 on Friday. The business has a fifty day simple moving average of $2.31 and a 200 day simple moving average of $2.56. VistaGen Therapeutics has a 12-month low of $1.90 and a 12-month high of $4.21. The firm has a market cap of $58.32 million, a P/E ratio of -1.20 and a beta of 0.70.
Analysts Set New Price Targets
Separately, William Blair reaffirmed an "outperform" rating on shares of VistaGen Therapeutics in a research report on Wednesday.
Get Our Latest Analysis on VistaGen Therapeutics
Institutional Inflows and Outflows
A hedge fund recently raised its stake in VistaGen Therapeutics stock. Bank of America Corp DE lifted its holdings in VistaGen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) by 1,068.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,141 shares of the company's stock after acquiring an additional 19,331 shares during the period. Bank of America Corp DE owned approximately 0.08% of VistaGen Therapeutics worth $62,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 78.39% of the company's stock.
About VistaGen Therapeutics
(
Get Free Report)
Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.
Further Reading
Before you consider VistaGen Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VistaGen Therapeutics wasn't on the list.
While VistaGen Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
